Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-04691502

Known as: PI3K/mTOR Kinase Inhibitor PF-04691502 
An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BackgroundThis phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and… Expand
  • table 2
  • table 3
  • table 4
  • figure 1
  • figure 2
2016
2016
OBJECTIVE PF-04691502 and gedatolisib (PF-05212384) are potent, dual PI3K/mTOR inhibitors. This phase II study (B1271004) was… Expand
  • figure 1
  • table 2
  • table 3
  • figure 2
2016
2016
Lung cancer is the leading cause of cancer deaths in both men and women in the United States accounting for about 27% of all… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2015
Highly Cited
2015
Signaling via the phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) is crucial for divergent… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Highly Cited
2013
Highly Cited
2013
Purpose: Phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway activation is often associated with… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2013
Highly Cited
2013
SummaryPurpose To determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary… Expand
  • table 2
  • table 1
  • table 3
  • figure 1
  • table 4
2013
2013
PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutations can help predict the antitumor activity of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
PI3K, AKT, and mTOR are key kinases from PI3K signaling pathway being extensively pursued to treat a variety of cancers in… Expand
  • table 1
  • table 3
  • table 4
  • table 5
  • table 6
Highly Cited
2012
Highly Cited
2012
Oncogenic PI3K/mTOR activation is frequently observed in human cancers and activates cell motility via p27 phosphorylations at… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2011
Highly Cited
2011
Deregulation of the phosphoinositide 3-kinase (PI3K) signaling pathway such as by PTEN loss or PIK3CA mutation occurs frequently… Expand
  • table 1